Crossmark Global Holdings, Inc. recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
3700 W SAM HOUSTON PKWY SOUTH SUITE 250 HOUSTON, TX 77042
As of the latest 13F report, the guru’s equity portfolio contained 1250 stocks valued at a total of $4.00Bil. The top holdings were AAPL(3.21%), MSFT(2.71%), and KO(1.56%).
According to GuruFocus data, these were Crossmark Global Holdings, Inc.’s top five trades of the quarter.
Intel Corp
Crossmark Global Holdings, Inc. reduced their investment in NAS:INTC by 420,763 shares. The trade had a 0.3% impact on the equity portfolio. During the quarter, the stock traded for an average price of $27.77.
On 01/20/2023, Intel Corp traded for a price of $28.42 per share and a market cap of $117.29Bil. The stock has returned -44.25% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Intel Corp has a price-earnings ratio of 8.74, a price-book ratio of 1.17, a price-earnings-to-growth (PEG) ratio of 0.63, a EV-to-Ebitda ratio of 5.01 and a price-sales ratio of 1.71.
The price-to-GF Value ratio is 0.65, earning the stock a GF Value rank of 10.
CVS Health Corp
Crossmark Global Holdings, Inc. reduced their investment in NYSE:CVS by 109,209 shares. The trade had a 0.29% impact on the equity portfolio. During the quarter, the stock traded for an average price of $96.48999999999999.
On 01/20/2023, CVS Health Corp traded for a price of $87.48 per share and a market cap of $114.95Bil. The stock has returned -12.74% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CVS Health Corp has a price-earnings ratio of 37.23, a price-book ratio of 1.63, a price-earnings-to-growth (PEG) ratio of 7.16, a EV-to-Ebitda ratio of 15.55 and a price-sales ratio of 0.37.
The price-to-GF Value ratio is 0.94, earning the stock a GF Value rank of 6.
Accenture PLC
During the quarter, Crossmark Global Holdings, Inc. bought 41,753 shares of NYSE:ACN for a total holding of 77,172. The trade had a 0.28% impact on the equity portfolio. During the quarter, the stock traded for an average price of $276.61.
On 01/20/2023, Accenture PLC traded for a price of $272.89 per share and a market cap of $171.85Bil. The stock has returned -19.40% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Accenture PLC has a price-earnings ratio of 24.79, a price-book ratio of 7.48, a price-earnings-to-growth (PEG) ratio of 1.94, a EV-to-Ebitda ratio of 15.63 and a price-sales ratio of 2.81.
The price-to-GF Value ratio is 0.80, earning the stock a GF Value rank of 9.
Kimberly-Clark Corp
Crossmark Global Holdings, Inc. reduced their investment in NYSE:KMB by 85,016 shares. The trade had a 0.27% impact on the equity portfolio. During the quarter, the stock traded for an average price of $127.05.
On 01/20/2023, Kimberly-Clark Corp traded for a price of $132.16 per share and a market cap of $44.60Bil. The stock has returned -4.13% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Kimberly-Clark Corp has a price-earnings ratio of 25.03, a price-book ratio of 101.66, a EV-to-Ebitda ratio of 16.57 and a price-sales ratio of 2.23.
The price-to-GF Value ratio is 0.92, earning the stock a GF Value rank of 6.
JPMorgan Chase & Co
Crossmark Global Holdings, Inc. reduced their investment in NYSE:JPM by 89,659 shares. The trade had a 0.26% impact on the equity portfolio. During the quarter, the stock traded for an average price of $126.71.
On 01/20/2023, JPMorgan Chase & Co traded for a price of $134.75 per share and a market cap of $395.40Bil. The stock has returned -6.80% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, JPMorgan Chase & Co has a price-earnings ratio of 15.83, a price-book ratio of 1.49, a price-earnings-to-growth (PEG) ratio of 2.36 and a price-sales ratio of 3.09.
The price-to-GF Value ratio is 0.91, earning the stock a GF Value rank of 6.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
